维普中文期刊产品整合服务

Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer:Current status in clinical trials

查看全文 作　　者：Yanlin [1]Song;Zhenfei [1]Bi;Yu [1]Liu;Furong [1]Qin;Yuquan [1]Wei;Xiawei [1]Wei 高影响力作者 机构地区：[1]Laboratory of Aging Research and Cancer Drug Target,State Key Laboratory of Biotherapy and Cancer Center,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu,Sichuan610041,China高影响力机构 出　　处：《Genes & Diseases》索引2023年第10卷第1期,共13页高影响力期刊 基　　金：This work is supported by the Key R&D Project of Sichuan Province,China(No.2020YFS0553);the National Science Fund for Excellent Young Scholars,China(No.32122052);the National Natural Science Foundation Regional Innovation and Development,China(No.U19A2003). 摘　　要：Molecular target inhibitors have been regularly approved by Food and Drug Administration(FDA)for tumor treatment,and most of them intervene in tumor cell proliferation and metabolism.The RAS-RAF-MEK-ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation,survival,and differentiation.The aberrant activation of the RAS-RAF-MEK-ERK signaling pathway induces tumors.About 33%of tumors harbor RAS mutations,while 8%of tumors are driven by RAF mutations.Great efforts have been dedicated to targeting the signaling pathway for cancer treatment in the past decades.In this review,we summarized the development of inhibitors targeting the RAS-RAF-MEK-ERK pathway with an emphasis on those used in clinical treatment.Moreover,we discussed the potential combinations of inhibitors that target the RAS-RAF-MEK-ERK signaling pathway and other signaling pathways.The inhibitors targeting the RAS-RAF-MEK-ERK pathway have essentially modified the therapeutic strategy against various cancers and deserve more attention in the current cancerresearchandtreatment. 关 键 词：Clinical trials Molecular target therapy RAS-RAF-MEK-ERK signaling pathway
相关文献

参考文献(202)

引证文献(14)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费